Your browser is no longer supported. Please, upgrade your browser.
Zogenix, Inc.
Index- P/E- EPS (ttm)-3.84 Insider Own0.10% Shs Outstand55.55M Perf Week-14.57%
Market Cap991.65M Forward P/E- EPS next Y-2.97 Insider Trans-11.63% Shs Float55.37M Perf Month-11.49%
Income-195.30M PEG- EPS next Q-1.03 Inst Own- Short Float14.24% Perf Quarter-4.99%
Sales7.10M P/S139.67 EPS this Y-198.20% Inst Trans5.47% Short Ratio8.75 Perf Half Y-35.57%
Book/sh7.60 P/B2.45 EPS next Y18.90% ROA-34.40% Target Price- Perf Year-67.06%
Cash/sh9.87 P/C1.89 EPS next 5Y8.80% ROE-51.30% 52W Range16.65 - 57.22 Perf YTD-6.75%
Dividend- P/FCF- EPS past 5Y-37.00% ROI-175.40% 52W High-67.42% Beta1.35
Dividend %- Quick Ratio6.10 Sales past 5Y-33.90% Gross Margin98.00% 52W Low11.95% ATR0.93
Employees141 Current Ratio6.10 Sales Q/Q383.30% Oper. Margin- RSI (14)37.89 Volatility5.28% 4.61%
OptionableYes Debt/Eq0.30 EPS Q/Q84.00% Profit Margin- Rel Volume1.38 Prev Close18.97
ShortableYes LT Debt/Eq0.30 EarningsNov 10 AMC Payout- Avg Volume901.24K Price18.64
Recom1.80 SMA20-7.18% SMA50-10.22% SMA200-22.26% Volume1,244,698 Change-1.74%
Aug-25-20Initiated Raymond James Mkt Perform
Mar-06-20Initiated Citigroup Neutral $27
Feb-07-20Reiterated Needham Buy $58 → $54
Feb-07-20Downgrade Ladenburg Thalmann Buy → Neutral $35
Oct-21-19Initiated Needham Buy $58
Jun-27-19Upgrade Guggenheim Neutral → Buy $40 → $64
Apr-09-19Downgrade Guggenheim Buy → Neutral
Nov-05-18Initiated Piper Jaffray Overweight
Sep-14-18Initiated BofA/Merrill Buy $63
Sep-12-18Initiated Northland Capital Outperform $70
Sep-07-18Initiated B. Riley FBR Buy $116
Aug-23-18Initiated Ladenburg Thalmann Buy $71
Aug-15-18Resumed Stifel Buy $65 → $69
Jul-13-18Reiterated Stifel Buy $55 → $65
Nov-27-17Initiated JMP Securities Mkt Outperform
Oct-03-17Reiterated Mizuho Buy $28 → $51
Sep-29-17Upgrade William Blair Mkt Perform → Outperform
Oct-04-16Resumed Leerink Partners Outperform $17
Aug-11-15Reiterated Oppenheimer Outperform $20 → $23
Jul-15-15Reiterated Brean Capital Buy $20 → $28
Jan-11-21 08:00AM  
Dec-22-20 05:12PM  
Dec-21-20 08:00AM  
Dec-17-20 04:39AM  
Dec-03-20 05:42PM  
Dec-01-20 08:00AM  
Nov-11-20 09:27AM  
Nov-09-20 10:30PM  
Nov-06-20 08:42AM  
Nov-03-20 03:27PM  
Nov-02-20 12:31PM  
Oct-29-20 08:00AM  
Oct-28-20 03:13PM  
Oct-26-20 08:00AM  
Oct-16-20 08:00AM  
Oct-15-20 04:16PM  
Oct-05-20 04:03PM  
Oct-02-20 08:00AM  
Sep-23-20 11:00PM  
Sep-22-20 04:14PM  
Sep-21-20 08:04PM  
Sep-11-20 11:32AM  
Sep-10-20 08:24AM  
Sep-09-20 12:33PM  
Aug-18-20 04:56PM  
Aug-05-20 10:15PM  
Jul-29-20 08:00AM  
Jul-28-20 12:33PM  
Jul-13-20 05:03PM  
Jul-05-20 03:45PM  
Jul-02-20 08:53AM  
Jul-01-20 09:43AM  
Jun-29-20 06:53PM  
Jun-26-20 10:48AM  
Jun-25-20 11:05PM  
Jun-21-20 02:53PM  
Jun-19-20 10:09PM  
Jun-12-20 08:00AM  
Jun-10-20 06:19AM  
Jun-03-20 03:10AM  
May-28-20 11:24AM  
May-27-20 09:37PM  
May-15-20 08:00AM  
May-06-20 06:00PM  
May-05-20 07:05PM  
May-04-20 08:55AM  
Apr-28-20 12:56PM  
Apr-20-20 08:00AM  
Apr-16-20 09:46AM  
Apr-15-20 08:00AM  
Apr-07-20 02:16PM  
Mar-29-20 12:31PM  
Mar-24-20 07:52AM  
Mar-21-20 09:08AM  
Mar-06-20 04:05PM  
Mar-05-20 11:09AM  
Mar-03-20 09:05PM  
Mar-02-20 04:01PM  
Feb-28-20 07:28AM  
Feb-27-20 04:27PM  
Feb-24-20 08:00AM  
Feb-11-20 11:27AM  
Feb-07-20 04:14PM  
Feb-06-20 04:01PM  
Jan-23-20 12:18PM  
Dec-26-19 11:53AM  
Dec-17-19 07:04PM  
Dec-05-19 08:15AM  
Dec-04-19 12:42PM  
Dec-02-19 04:01PM  
Nov-27-19 08:00AM  
Nov-25-19 09:13AM  
Nov-21-19 02:42PM  
Nov-18-19 04:43PM  
Nov-12-19 08:00AM  
Nov-07-19 07:35PM  
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). Zogenix, Inc. has collaboration with Tevard Biosciences to advance novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GARNER CAM LDirectorNov 19Buy20.138,000161,04216,000Nov 20 05:15 PM
TANNENBAUM RENEE PDirectorNov 17Sale20.7415,000311,06632,872Nov 18 05:05 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERJul 02Option Exercise0.003,750010,232Jul 06 04:37 PM
Galer Bradley S.EVP/Chief Medical OfficerJun 25Option Exercise0.0010,000020,015Jun 29 09:53 PM
Farfel Gail MEVP/Chief Development OfficerJun 25Option Exercise0.008,750014,223Jun 29 09:54 PM
Farfel Gail MEVP/Chief Development OfficerMay 12Sale28.212,57372,5845,048May 13 05:39 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERMay 08Buy25.451,00025,4505,913May 11 06:18 PM
WIGGINS MARK CDirectorMar 23Buy20.482,50051,1962,500Mar 24 04:38 PM
FARR STEPHEN JPresident and CEOMar 19Option Exercise10.359,66199,99165,251Mar 20 04:01 PM
FARR STEPHEN JPresident and CEOMar 19Sale18.516,158113,96455,590Mar 20 04:01 PM
Galer Bradley S.EVP/Chief Medical OfficerMar 18Buy19.691,00019,68510,015Mar 20 04:01 PM
FARR STEPHEN JPresident and CEOMar 15Option Exercise0.0010,000064,228Mar 17 07:25 PM
Galer Bradley S.EVP/Chief Medical OfficerMar 15Option Exercise0.003,59509,573Mar 17 07:25 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERMar 15Option Exercise0.002,03205,517Mar 17 07:25 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Mar 15Option Exercise0.003,59504,207Mar 17 07:24 PM
Farfel Gail MEVP/Chief Development OfficerMar 15Option Exercise0.003,65708,317Mar 17 07:24 PM
GARNER CAM LDirectorMar 13Buy21.838,000174,6478,000Mar 18 05:48 PM